Sami Said, M by naq52275

VIEWS: 0 PAGES: 3

									Sami Said, M.D.

Training:
Residency - Internal Medicine. University Hospital. Cairo,
Egypt. NYU-Bellevue Medical Center. NY, NY.
Fellowship - Cardiology, NYU-Bellevue Medic al Center. NY,
NY. 1955-1957
Fellowship - Pulmonary, Johns Hopkins Medical School.
Baltimore, MD. 1957-1958
Visiting Scientist, Karolinska Institute. Stockholm, Sweden.
1968-1970


Professional Appointments:
Professor of Medicine, Physiology & Biophysics, SUNY-Stony
Brook. Faculty member since 1991.
Professor, Graduate Program in Pharmac ology, SUNY-Stony
Brook.
Assistant Chief of Staff, Research and Development, Northport VAMC.

Interests:
Acute lung injury (ARDS) with special reference to mechanisms and prevention; Cell injury/cell
death; Asthma; Vasoactive Intestinal Peptide (VIP ) and related peptides. Alzheimer's disease;
Teaching.


Ongoing Research Projects:
Apoptosis in acute lung injury
Estrogen prot ection of the lung
VIP and glutamate in airway inflammation and asthma
Clinical trial of VIP in the Acute Respiratory Distress Sy ndrome (ARDS)

E-mail: ssaid@notes.cc.sunysb.edu


Sami Said has published with his co-workers more than 370 scientific articles describing the
biology of neurotransmitters, in particular that of the vasoactive intestinal peptide (VIP; A viptadil).
His work wit h VIP began with its discovery, first in the lung and intestine, then in the brain and
nerve cells. Research on VIP and related peptides has taken him and his colleagues on an
exciting journey through many organ systems and across different disciplines, including
physiology, pharmacology, biochemistry, endocrinology, and neuroscience.


Prof. Said is Chairman of the National Organization for Rare Disorders (NORD) Medical Advisory
Committee. NORD is a unique federation of voluntary health organizations in the United States
dedicated to helping people with rare "orphan" diseases and assisting the organizations that
serve them. NORD is committed to the identification, treatment, and cure of rare disorders
through programs of education, advocacy, research, and service.


Dr. Sami I. Said is appointed Distinguished Professor by the State University of New York for his
seminal work on Vasoactive Intestinal Peptide (VIP; A vipt adil).


The appointment was granted by the State University of New York Board of Trustees on
November 28, 2006 for: "Your seminal work in the field of Medicine especially your
groundbreaking scholars hip on the pharmacology of the Vasoactive Intestinal Peptide (V IP), a
vasodilator new to science, was the impet us of your designation."


Dr. Sami I. Said M. D. is professor in the departments of Medicine, Physiology, and Graduate
Program in Pharmacology at Stony Brook University, and Faculty member since 1991. Born and
educated in Cairo, Egypt, he moved to New York University Bellevue Medical Cent er for
residency in internal medicine and a fellowship in Cardiology, followed by a fellowship in
Pulmonary Physiology at Johns Hopkins Medical School. In 1969 together with Professor Viktor
Mutt at Karolinska Institute in Stockholm Sweden he discovered VIP (A viptadil). His entire life
since then has been dedicat ed to A vipt adil in rare diseases with emphasis on the respiratory
system.


Latest publications:


Hamidi SA, Prabhakar S, Said SI.
Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene
deletion.
Eur Respir J. 2008 Jan;31(1):135-9.

Said SI.
The discovery of VIP: initially looked for in the lung, isolated from intestine, and
identified as a neuropeptide.
Peptides. 2007 Sep;28(9):1620-1.

Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, C hen JJ,
Waschek JA, Kort S.
Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal
peptide gene.
Circulation. 2007 Mar 13;115(10):1260-8.
Hamidi SA, Szema AM, Lyubsky S, Dickman KG, Degene A, Mathew SM, Waschek JA,
Said SI.
Clues to VIP function from knockout mice.
Ann N Y Acad Sci. 2006 Jul;1070:5-9.

Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, Chen JJ,
Waschek JA, Said SI.
Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation,
partially reversible by VIP.
Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L880-6.

Said SI.
Mediators and modulators of pulmonary arterial hypertension.
Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L547-58.

								
To top